A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
2022 · Nature Cancer · 124 citations
https://doi.org/10.1038/s43018-022-00439-1
A
Anosheh Afghahi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
88
Papers
926
Citations
16
h-index
24
i10-index
Anosheh Afghahi is an academic researcher from Flatiron Health (United States). The author has contributed to research in topics: BRCA gene mutations in cancer & Breast Cancer Treatment Studies & Cancer Genomics and Diagnostics. The author has an h-index of 16, co-authored 75 publications.
ORCID: 0000-0003-1225-406XPapers by this author
worksTargeted Therapy for Cancer in the Genomic Era
2015 · The Cancer Journal · 50 citations
https://doi.org/10.1097/ppo.0000000000000135
Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer
2015 · Breast Cancer Research · 25 citations
https://doi.org/10.1186/s13058-015-0623-y
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
2023 · npj Breast Cancer · 14 citations
https://doi.org/10.1038/s41523-023-00544-z
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy
2023 · Breast Cancer Research and Treatment · 10 citations
https://doi.org/10.1007/s10549-023-06978-0
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
2025 · Blood Cancer Journal · 4 citations
https://doi.org/10.1038/s41408-025-01256-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat